28.9 C
Vientiane
Sunday, July 27, 2025
spot_img
Home Blog Page 472

Vietnam: A Hub for Accessible World-Class British Transnational Education for Resilient Global Graduates

HANOI, Vietnam, April 28, 2025 /PRNewswire/ — Vietnam is emerging as a leading destination for affordable British transnational education (TNE) in Southeast Asia, offering high-quality local programmes that develop resilient global graduates.

British University Vietnam (BUV) is recognised by the British Council as an exemplary foreign-invested university by offering degrees from renowned UK universities.
British University Vietnam (BUV) is recognised by the British Council as an exemplary foreign-invested university by offering degrees from renowned UK universities.

Vietnam hosts 28 self-licensed TNE universities and eight foreign-invested institutions over the last two decades. Among them, British University Vietnam (BUV) boasts a 100% graduate employment rate within three months, while RMIT Vietnam serves over 12,000 students and has 20,000 alumni since 2000.

Vietnam’s Leadership in UK Transnational Education

Within this landscape, the UK plays a leading role. According to the 2024 British Council report, Vietnam is now the 5th largest UK TNE market in East Asia and 3rd in Southeast Asia. It’s also a priority country in the UK’s International Education Strategy.

Vietnam’s TNE programmes follow strict partner-country standards, offering flexible, student-centred learning and industry-relevant skills that boost employability.

BUV, recognised by the British Council as an exemplary foreign-invested university, offers degrees from prestigious UK institutions such as the University of London (with academic direction from LSE), Bournemouth University, and more.

These programmes equip graduates with globally valued qualifications. BUV remains the only university in Vietnam formally accredited by QAA, following a rigorous year-long process that included site visits to its 5-star Ecopark campus.

Driving Graduate Success

As a leading UK TNE example in Vietnam, BUV equips students with practical skills, global exposure, and internationally recognised qualifications – preparing them to succeed across startups, corporates, and academia.

BUV alumni have built successful startups across diverse industries, from business, creative industries, marketing, retail, to technology and hospitality. Many have rapidly expanded their businesses with multiple branches in Vietnam and have taken their ventures to international markets.

In the corporate sector, BUV graduates hold high-level leadership roles at major companies. In Vietnam, they contribute to leading firms like VinFast, Samsung, Nestlé, etc. Internationally, they work at top corporations such as PwC, KPMG, McKinsey, Generali, etc. demonstrating their ability to lead in both local and global business environments.

Academically, BUV alumni have secured prestigious doctoral positions and graduated with master’s degrees with scholarships at world-renowned institutions, including the University of Oxford, the University of Colorado Boulder, the University of Sydney, and the University of Strathclyde, etc.

“At BUV, we offer quality British education that nurtures dreams and builds resilience,” said Professor Raymond Gordon, Vice-Chancellor and President of BUV. “Our graduates exemplify the transformative power of TNE, equipped to thrive in a dynamic global world.”

A Benchmark for Excellence

BUV’s achievements rest on academic excellence and international quality. BUV stands out for its exceptional standards as the first university in Vietnam and ASEAN accredited by the UK’s QAA, and the first in Vietnam to receive a 5-Star Excellence Rating from QS. Over 60% of faculty hold doctorates, bringing global experience that enriches student learning.

Students benefit from strong career support, global exposure through 400+ industry partners, and nearly 50 partner universities including Russell Group institutions.

Located in the eco-friendly Ecopark, just 25 minutes from central Hanoi, BUV’s 85 million USD campus is Vietnam’s first to earn EDGE Advanced certification. It features cutting-edge facilities and technology that meet top global standards.

BUV offers up to 100% scholarships for outstanding undergraduate and postgraduate international students holding foreign passports. Applications for autumn 2025 close on June 30, 2025.

International students receive airport pickup, orientation, and accommodation in Ecopark. The Global Buddy programme matches them with local peers for support, while clubs, cultural trips, career counselling, and mental health services help students thrive in a global environment.

For more information: https://www.buv.edu.vn/scholarships/global-pathfinders-scholarship/

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR meeting will take place April 25-30, 2025, in Chicago, Illinois.

Dr. Kaijie He, Cancer Biology and ADC Vice President of Innovent, stated: “With continuous advancement of Innovent Academy’s integrated technology platforms, our global R&D capabilities have reached new heights, further strengthening our competitive position in the international biopharmaceutical landscape. This progress has accelerated our ability to design and develop innovative therapeutic candidates with significant global impact. We are proud to showcase a batch of preclinical research findings at this year’s AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs). These scientific advancements highlight our expanding research expertise and underscore our unwavering dedication to creating life-changing treatments for patients across the globe. Moving forward, we remain deeply committed to scientific innovation—advancing target selection precision and pioneering unexplored biological mechanisms—to deliver breakthrough solutions for difficult-to-treat diseases and ensure more patients worldwide can access the benefits of cutting-edge therapeutic technologies. ” 

Research highlights as below:

Late-Breaking Research: Immunology 2
Topic: Preclinical data of IAR037, a novel CD40/PD-L1 bispecific antibody for the treatment of advanced solid tumors resistant to immune checkpoint inhibitors
Abstract Number: LB139
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 52

IAR037 is a novel CD40/PD-L1 bispecific antibody, which simultaneously activates CD40 and blocks PD-1/L1, demonstrating potent anti-tumor efficacy in PD-1-resistant syngeneic mouse models and synergy with PD-1/IL-2α-bias fusion protein IBI363. Preclinical studies show tumor-specific immune activation with minimal systemic effects and a favorable safety profile in cynomolgus monkeys.

IAR037 presents a novel therapeutic approach for ICI-resistant advanced solid tumors and the IND-enabling study of IAR037 is ongoing.

Late-Breaking Research: Clinical Research 1
Topic: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors
Abstract Number: LB222
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 53

IBI3010 is a FRα targeting biparatopic ADC with novel topoisomerase I inhibitor NT1 (DAR8). The biparatopic design enhances tumor binding/internalization.

IBI3010 shows superior cytotoxicity and bystander effect versus mirvetuximab soravtansine (IMGN853) in vitro. IBI3010 demonstrated superior antitumor activity to IMGN853 in FRα-expressing CDX models, particularly in low-FRα expression models. GLP tox studies in cynomolgus monkeys established 60 mg/kg as HNSTD with full tolerability.

These data support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors.

Poster Session: Experimental and Molecular Therapeutics – Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies
Topic: IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models
Abstract Number: 344
Presentation Form: Poster
Presentation Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 16
Poster Board Number: 11

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell infiltration.

In CDX models with varying TROP2/PD-L1 expression, IBI3014 demonstrated superior cytotoxicity compared to benchmark ADCs, covering broader tumor types. It maintained stability in mice and monkeys, with a well-tolerated HNSTD of 50 mg/kg in monkeys.

IBI3014’s dual mechanism of action not only enhances therapeutic efficacy but also maintains a favorable safety profile, which provides a promising approach for cancer therapy.

Poster Session: Experimental and Molecular Therapeutics – Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies
Topic: Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers
Abstract Number: 345
Presentation Form: Poster
Presentation Time: Sunday April 27, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 16
Poster Board Number: 12

IBI3022, a bi-specific ADC targeting Trop2 and B7H4, aims to enhance tumor antigen expression and reduce off-tumor toxicity associated with Trop2 by incorporating a single-arm Trop2 antibody and a less toxic Topoi NT3 linker payload.

In vitro studies demonstrate that IBI3022 exhibits superior cytotoxicity in HT29 cells overexpressing Trop2 and B7H4 compared to mono-specific ADC benchmarks targeting Trop2 or B7H4. In vivo, IBI3022 demonstrates enhanced tumor suppression compared to mono-specific ADC benchmarks in various tumor models with differing levels of Trop2 and B7H4 expression.

IBI3022 represents a promising bi-specific ADC for the treatment of gynecologic cancers, offering improved efficacy and safety profiles.

Poster Session: Experimental and Molecular Therapeutics – Therapeutic Approaches to Attack the Tumor Microenvironment
Topic: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the breaks in immune response and strongly activating T and NK cells in the tumor microenvironment
Abstract Number: 3118
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 24
Poster Board Number: 2

IBI3026 is a bispecific immune agonist targeting PD-1 and IL-12 receptor, designed to improve safety profile by reducing IL-12 activity while enabling tumor-targeted activation through PD-1+ T cell enrichment.

IBI3026 demonstrated potent immune activation (STAT4/IFN-γ signaling) in pre-treated human PBMCs and achieved complete tumor suppression in multiple models (EMT6, CT26, A375, BxPC-3). In cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) of IBI3026 is 150 mg/kg and the calculated therapeutic index is 63.

As a first-in-class candidate, IBI3026 combines PD-1 blockade with localized IL-12 activation, offering a promising strategy for tumors resistant to current immunotherapies.

Poster Session: Immunology – T Cell Engagers
Topic: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy
Abstract Number: 3510
Presentation Form: Poster
Presentation Time: Monday April 28, 2025, 2:00 PM – 5:00 PM
Location: Poster Section 38
Poster Board Number: 18

We developed a 2+1 format MUC16 TCE, with improved tumor cell binding affinity, enhanced tumor cell killing potency, and MUC16-dependent T cell binding and activation.

Compared to the benchmark molecule, this MUC16 TCE showed limited T cell binding and activation without MUC16, minimizing off-target activity. This 2+1 format MUC16 TCE also showed a favorable pharmacokinetics profile in mice. Functionally, systemic administration of this MUC16 TCE showed superior anti-tumor efficacy, with undetectable toxicity, in xenograft models.

This innovative TCE shows significant potential for treating MUC16-positive cancers, particularly chemotherapy-resistant ovarian cancer.

Poster Session: Experimental and Molecular Therapeutics – New and Emerging Cancer Drug Targets
Topic: IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies
Abstract Number: 4249
Presentation Form: Poster
Presentation Time: Tuesday April 29, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 17
Poster Board Number: 6

IBI3019 is a novel tri-specific antibody targeting EGFR, CDH17, and CD16A for colorectal cancer treatment. It demonstrated strong tumor-specific EGFR inhibition by targeting the overexpressed CDH17 on tumors, while significantly reducing skin toxicities commonly associated with EGFR therapies.

Additionally, IBI3019 incorporates a high-affinity CD16A nanobody that showed better antibody-dependent cell cytotoxicity than those mediated by low-fucose Fc. Importantly, IBI3019 not only demonstrated superior in vitro and in vivo anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in a pilot tox study. These promising preclinical findings warrant further clinical exploration.

Poster Session: Immunology – Modulation of Tumor Microenvironment: Modulation of Lymphocyte Influx
Topic: A PD1-IFNα fusion protein, with an attenuated IFNα fused to a clinically validated PD1 mAb, elicited PD1-dependent IFNα signaling and superior anti-tumor efficacy
Abstract Number: 4881
Presentation Form: Poster
Presentation Time: Tuesday April 29, 2025, 9:00 AM – 12:00 PM
Location: Poster Section 40
Poster Board Number: 9

We engineered a novel PD1-IFNα fusion protein that combines attenuated IFNα with Sintilimab, inducing potent PD1/PDL1 blockade while eliciting highly PD1-dependent IFNα signaling, selectively activating in PD1-high cells.

Preclinical studies demonstrate superior anti-tumor efficacy compared to PD1 mAb alone in multiple mouse syngeneic tumor models, with undetectable toxicity and a favorable pharmacokinetics profile.

This bi-functional molecule potentially benefits patients with ICB-refractory cancers including pancreatic, ovarian, and MSS colorectal cancers.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2 Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics (“Innovent”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

Nona Biosciences’ Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025

CAMBRIDGE, Mass., April 28, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisomerase 1 inhibitor (TOP1i)-based antibody-drug conjugate (ADC) targeting mesothelin (MSLN), at the AACR Annual Meeting 2025. This ADC was originally developed using Nona Biosciences’ proprietary Harbour Mice® and integrated ADC platforms. Pfizer acquired its global clinical development and commercialization rights on December 14, 2023.

Poster Presentation at AACR Annual Meeting 2025
Title: PF-08052666 (HBM9033), a first-in-class topoisomerase 1 inhibitor-based ADC targeting MSLN, demonstrates potent antitumor activity in preclinical models of ovarian, lung, and colorectal cancers
Abstract Number: 324
Poster Board Number: 16
Session Title: Antireceptors and Other Biological Therapeutic Agents
Session Date: April 27, 2025

PF-08052666 was designed to address the limitations of earlier anti-MSLN ADCs through a novel antibody, differentiated linker-payload, and a higher drug-to-antibody ratio (DAR). It consists of a human IgG1 monoclonal antibody conjugated to a potent camptothecin-based TOP1i payload with a protease-cleavable linker, achieving an average DAR of 8.

Key Preclinical Findings Presented at AACR Annual Meeting 2025

  • In vitro, PF-08052666 demonstrated direct cytotoxicity through delivery of payload to MSLN-positive cells, bystander killing activity on co-cultured MSLN-negative cells, and maintained cytotoxicity even in the presence of physiologically relevant concentrations of soluble MSLN.
  • In vivo, PF-08052666 outperformed a DM4-based anti-MSLN benchmark ADC in both cell-line and patient-derived xenograft models across multiple tumor types, including ovarian, lung, and colorectal cancers.
  • PF-08052666 also outperformed the DM4-based anti-MSLN benchmark ADC in heterogeneous xenograft models consisting of ad-mixed MSLN-positive and MSLN-negative cells, demonstrating the increased bystander activity of the novel linker-payload of MesoC2.

These promising preclinical results support the ongoing first-in-human phase 1 clinical trial of PF-08052666 in patients with advanced solid tumors (NCT06466187), which is currently enrolling participants.

“The preclinical data on PF-08052666 presented by Pfizer at AACR 2025 reflects the strength of our technology platforms and our dedication to advancing transformative therapies,” said Jingsong Wang, MD, PhD, Chairman of Nona Biosciences. “By leveraging our industry-leading technology platforms, we continue to drive innovation that enables the development of next-generation biotherapeutics. We look forward to further collaboration with Pfizer to accelerate breakthroughs that address critical medical needs.”

About PF-08052666 (HBM9033)

PF-08052666 is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in PF-08052666 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning PF-08052666 as a potential globally best-in-class therapeutic option.

About Nona Biosciences

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.

Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.

Everest Medicines Announces the “B” Marker Removal from Company’s Stock Code, Effective May 2, 2025

SHANGHAI, April 28, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the “B” marker will cease to be affixed to the Company’s stock short name, effective May 2, 2025. The removal of “B” marker was granted by The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) on April 22, 2025.

Everest Medicines was listed on the Stock Exchange in October 2020. Over the past three years, Everest has established and continuously deepened its “Dual-Engine” strategy. Evolving from an initial license-in model, the Company has developed a balanced approach that integrates in-house discovery with global partnerships and in-licensing, with a focus on high-value areas and the development of first-in-class or best-in-class assets. With global rights to EVER001, the Company will actively explore partnership opportunities to leverage international expertise and optimize commercial value, while further enhancing its global visibility and market presence. Everest will utilize its efficient commercial platform to solidify its leadership in key therapeutic areas, advance innovation on its mRNA platform, and strive to become a leading biopharma in the Asia-Pacific region by 2030.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

 

Hikvision releases 2024 full-year and 2025 first-quarter financial results

HANGZHOU, China, April 27, 2025 /PRNewswire/ — Hikvision has announced its full-year financial results for 2024 and first-quarter results for 2025. In 2024, the company reported total revenue of RMB 92.496 billion, marking a 3.53% year‑over‑year (YoY) growth. In the first quarter of 2025, the company reported revenue of RMB 18.532 billion, up 4.01% YoY. Net profit attributable to shareholders reached RMB 2.039 billion, reflecting a 6.41% YoY increase.

Hikvision releases 2024 full-year and 2025 first-quarter financial results
Hikvision releases 2024 full-year and 2025 first-quarter financial results

Over the past two decades, Hikvision has established itself as a global security leader, developing a robust AIoT ecosystem encompassing over 30,000 products. Today, the company remains committed to steady and solid progress, navigating uncertainties with a positive and prudent approach. It maintained its leading position in the domestic security market while seeking growth from overseas markets and innovative businesses. With profitability as a central focus, the company is driving organizational transformation and refining management practices to support long-term, sustainable growth. Notably, Hikvision is at the forefront of leveraging breakthroughs in large-scale AI model technologies to accelerate scenario-based digitalization across diverse industries.

Throughout the past year, the company strengthened its overseas presence, with main business revenue from international markets rising to RMB 25.989 billion, accounting for 28.10% of total revenue and reflecting an 8.39% YoY growth. Hikvision’s overseas revenue spans over 180 countries and regions, with developing markets contributing more than 70% of that total. The steady increase of overseas business revenue has emerged as an important driver of the company’s overall profit growth. Meanwhile, Hikvision’s innovation businesses continued to grow rapidly, with revenue reaching RMB 22.484 billion.

In 2024, Hikvision continued to prioritize research and development, investing RMB 11.864 billion in R&D, accounting for 12.83% of its total revenue. Over the years, the company has built a multi-level R&D system with the headquarters’ R&D capabilities at the core, radiating to key regions both domestically and internationally.

In its latest developments, Hikvision is actively advancing AIoT technologies, with its Guanlan Large-Scale AI Models integrating vision, language, and multimodal capabilities, among others. These innovations have significantly enhanced both perception and cognition abilities of Hikvision’s products and solutions. For instance, in perimeter protection, the large vision model can achieve a 90% reduction in false alarms.

Looking ahead, Hikvision is committed to a strategy of high-quality growth, with a stronger focus on driving innovation, enhancing efficiency and ensuring long-term sustainability.

Click here for more information.

TCL Electronics (01070.HK) Global TV Shipment and Sales Revenue Maintain High Growth in 2025Q1

Continued Product Mix Optimisation Yields Over 230% YoY Expansion in Global Shipment of Mini LED TV

HONG KONG, April 27, 2025 /PRNewswire/ — TCL Electronics Holdings Limited (“TCL Electronics” or the “Company”, 01070.HK) today announced its global TV shipment data for the first quarter of 2025. Driven by the dual-brand strategy of “TCL + Falcon” and the intensified execution of its “mid-to-high-end and large-screen” positioning, alongside sustained advances in product competitiveness complemented by Mini LED, QLED, AI and other cutting-edge technologies, the Company achieved a solid start to the year. The global shipment of TCL TV reached 6.51 million sets, representing a year-on-year (“YoY”) increase of 11.4%. Benefitting from the increase in the shipment proportion of large-screen and high-end products, the sales revenue of TCL TV increased by 22.3% YoY in the first quarter.

Technological Advancements Elevate Competitive Positioning, Large-Screen and Mid-to-High-End TVs Gain Further Global Popularity

Capitalising on the global shift towards large-screen and high-end products, TCL Electronics has driven significant growth in the shipment of large-screen and high-end product series. In the first quarter of 2025, the global shipment of 65-inch and above TCL TV grew by 33.0% YoY, with its shipment proportion rising by 4.5 percentage points to 27.7%. The global shipment of 75-inch and above TCL TV exhibited even more pronounced acceleration, surging by 41.6% YoY, with the corresponding shipment proportion up by 2.9 percentage points to 13.7%. The average screen size of global shipment of TCL TV increased by 1.9 inches YoY to 53.4 inches.

The Company also continued to deepen its technological infrastructure in high-end display products. Its flagship Mini LED TV is equipped with next-generation features such as the CrystGlow WHVA Panel and All-domain Halo Control Technology, delivering enhanced contrast, minimised reflection, wider viewing angles and seamless screen borders. These innovations significantly enriched picture quality and colour accuracy, greatly enhancing the users’ visual experience. The exceptional consumer response to these innovations has been demonstrated trough robust global market acceptance. In the first quarter of 2025, global shipment of TCL QLED TV rose by 74.9% YoY to 1.33 million sets, while the global shipment of TCL Mini LED TV surged by 232.9% YoY to approximately 0.55 million sets.

Domestic and Overseas Markets Both Record Double-Digit Growth in Shipment While Global Market Share in Multiple Regions Takes the Lead in the Industry

In the PRC market, driven by sustained brand development and technology-led product innovation, TCL TV shipment in the PRC market expanded by 10.8% YoY in the first quarter of 2025. Meanwhile, the strategy of focusing on large-screen and mid-to-high-end products has yielded remarkable results, with continuous improvement in the product structure. Notably, the shipment of 65-inche and above TCL TV grew by 18.3%, rising by 3.5 percentage points to 54.7% of total domestic shipment, while the shipment of 75-inch and above TCL TV rose by 21.0% YoY, with the proportion of shipment increasing by 3.0 percentage points to 34.9%. The shipment of TCL Mini LED TV has surged by 341.1% YoY, with its shipment proportion substantially increasing by 13.2 percentage points to 17.6%. In the first quarter of 2025, the market share in terms of retail sales revenue and retail sales volume of TCL TV in the PRC market rose to 23.1% and 22.1%, respectively, both ranking among the top two in the PRC market[1]. Continuous improvement of the product mix has driven the further increase in sales revenue.  In the first quarter, the sales revenue of TCL TV in the PRC market increased by 35.4% YoY, and the average selling price rose by 22.2% YoY.

In terms of the international market, TCL officially announced that it had become a Worldwide Olympic Partner in February 2025, marking a significant milestone in enhancing its global brand awareness and influence. TCL will deliver comprehensive technological infrastructure, advanced product solutions and specialised professional services to support Olympic Games operations across multiple smart device categories such as TVs, air conditioners, refrigerators and washing machines. This strategic partnership, coupled with precise sports marketing deployment, strategic event sponsorship and a systematic construction of its global customer management system, further strengthened global marketing effectiveness. In the first quarter of 2025, TCL TV shipment in international market grew by 11.6% YoY. The shipment of large-screen TV showed particularly strong YoY momentum, with 65-inch and above TCL TV increasing by 48.5% YoY and 75-inch and above TCL TV surging by 86.8%. The significant rise of the shipment of large-screen TCL TV stimulated the sales revenue of TCL TV in the international market increasing by 17.2% YoY.

By region, the European market has achieved rapid breakthrough by precisely laying out regional channel networks through a “one-country-one-policy” approach. The shipment of TCL-branded TV in the European market increased by 15.8% YoY, with the shipment of 75-inch and above TCL TV surging by 74.4%. TCL TV ranked among the top two in retail sales volume in France, Poland and Sweden[2], while ranked third in Spain, Romania, Greece, and the Czech Republic[2]. In emerging markets, encompassing Asia-Pacific, Latin America, and the Middle East and Africa, further optimisation of the sports marketing matrix and continued upgrades to sales and retail channels led to a 18.8% YoY rise in the shipment of TCL TV, with the shipment of 75-inch and above TCL TV surging by 100.5%. TCL TV secured the No.1 position in retail sales volume in Australia and the Philippines, and ranked among the top two in Brazil, Pakistan, Saudi Arabia, Thailand and Myanmar, while ranked third in Argentina, Vietnam, and South Korea[2]. In North America, the Company has strategically pivoted to focus on mid-to-high-end distribution channel penetration. While this recalibration resulted in a modest 3.8% YoY decline in TV shipment, the implementation of mid-to-high-end strategy has yielded significant results in the large-screen segments. The shipment of 75-inch and above TCL TV increased by 79.3% YoY, with its shipment proportion rising by 5.8 percentage points to 12.5%. TCL TV maintained a top-two retail market share in the United States[3].

Harnessing enduring winds with steadfast resolve, and soaring ever higher with bold ambition. TCL Electronics will continue to pursue its strategy of “Lead with Brand Value, Excel in Global Efficiency, Drive with Technology, Thrive on Global Vitality”. The Company remains strategically aligned with its consumer-centric value creation imperative, adhering to its mid-to-high-end development roadmap through continuous refinement of its product portfolio, accelerated research and development investment, precision-calibrated regional strategies and enhanced global localisation, as it advances resolutely towards becoming a truly global leading enterprise.

TV Shipment Data for the First Quarter  of 202 5 (unaudited)

Unit: Set

2025 Q1

2024 Q1

Large-sized display – Global Shipment of TCL TV

6,507,078

5,840,635

– Proportion of 65 inches and above TCL TV by global shipment

27.7 %

23.2 %

       – Proportion of 65 inches and above TCL TV by shipment in the PRC market

54.7 %

51.2 %

       – Proportion of 65 inches and above TCL TV by shipment in the international market

19.6 %

14.7 %

– Proportion of 75 inches and above TCL TV by global shipment

13.7 %

10.8 %

       – Proportion of 75 inches and above TCL TV by shipment in the PRC market

34.9 %

31.9 %

       – Proportion of 75 inches and above TCL TV by shipment in the international market

7.3 %

4.4 %

– Proportion of TCL Mini LED TV by global shipment

8.8 %

3.0 %

       – Proportion of TCL Mini LED TV by shipment in the PRC market

17.6 %

4.4 %

       – Proportion of TCL Mini LED TV by shipment in the international market

6.0 %

2.5 %

About TCL Electronics

TCL Electronics Holdings Limited (01070.HK, incorporated in the Cayman Islands with limited liability) was listed on the mainboard of the Hong Kong Stock Exchange in November 1999. It is engaged in display business, innovative business and internet business. TCL Electronics actively transforms and innovates under the strategy of “Lead with Brand Value, Excel in Global Efficiency, Drive with Technology, Thrive on Global Vitality”. Focusing on the mid-to-high-end markets around the world, the Company strives to consolidate the “Intelligent IoT Ecosystem” strategy and is committed to providing users with an all-scenario smart and healthy life while developing into a world-leading smart technology company. TCL Electronics is part of the Shenzhen-Hong Kong Stock Connect program and is included in the Hang Seng Stock Connect Hong Kong Index, the Hang Seng Composite MidCap & SmallCap Index and the Hang Seng Corporate Sustainability Benchmark Index. Besides, it has received Hang Seng Index’s ESG rating of A for consecutive years since 2018.

For more information, please visit the investor relations web page of TCL Electronics at   http://electronics.tcl.com or follow the Official Account of TCL Electronics investor relations.

[1] Data Source: Retail sales revenue and retail sales volume of TV brand of the first quarter of 2025 in the PRC market from CMM’s omni-channel data.

[2] Data Source: Retail sales volume in January 2025 to February 2025 from GfK.

[3] Data Source: Retail sales volume in January 2025 to February 2025 from Circana.

 

Hikvision releases 2024 ESG report, delivering THRIVE for a better future

HANGZHOU, China, April 27, 2025 /PRNewswire/ — Hikvision has published its 2024 Environmental, Social and Governance (ESG) Report, marking seven consecutive years of sharing its ESG commitments and practices. Notably, the THRIVE sustainability philosophy was introduced for the first time. Guided by “Tech for Good”, Hikvision outlines five focus areas — Harmony, Reliability, Integrity, Value Chain and Environment.

Hikvision releases 2024 ESG report, delivering THRIVE for a better future
Hikvision releases 2024 ESG report, delivering THRIVE for a better future

By thoroughly reviewing the global policies, ESG rating criteria and stakeholder perspectives, Hikvision identified 3 material topics: ‘Technological Innovation’, ‘Cybersecurity and Data Protection’, and ‘Response to Climate Change’.

Driving social progress through innovation

Hikvision has long explored innovative approaches to addressing social challenges. In urban governance, Hikvision has provided traffic management solutions across over 300 cities, optimizing traffic flow at over 53,000 intersections. In industrial digitalization, Hikvision partnered with CHN Energy to develop large-scale, real-time, and non-destructive bi-spectrum rapid coal quality analysis technology, overcoming the limitations of traditional methods.

With its STAR Program for Social Good, Hikvision leverages its technologies to preserve wildlife, environment and culture. By 2024, Hikvision has partnered with over 30 NGOs. Notable efforts include enhancing fire prevention at Lanxi Bridge, an ancient wooden bridge built in 1574, and upgrading the observation system at South Africa’s Kariega Game Reserve.

Enhancing the reliability of cybersecurity and data protection

Hikvision consistently prioritizes cybersecurity and data protection, a commitment that has been recognized by prestigious certifications, including ISO 27017, ISO 27018, DCMM, and IEC 62443-4-1, among others. 

Furthermore, Hikvision places a strong emphasis on skills and training. In 2024, Hikvision launched 26 cybersecurity-themed courses and conducted 171 training sessions, achieving 100% employee engagement. Hikvision is also fostering the next generation of talent by supporting the inaugural Hackathon at ISE 2025 in Barcelona.

Tackling climate change with low-carbon strategies

Hikvision integrates decarbonization strategies into its corporate policies, establishing a carbon-neutral business blueprint focused on low-carbon products, intelligent manufacturing, green operations, and digital transformation.

Key milestones include Hikvision’s Carbon Footprint Verification for 103 models and the world’s first certification for Carbon Footprint of Product Process from Bureau Veritas. 16 of Hikvision’s LED displays received the Green Product Mark certification issued by TÜV Rheinland, making them the first in the LED display industry to achieve this distinction.

Hikvision remains committed to sustainability, laying a solid foundation for stable operations and shared value. With ongoing initiatives, we THRIVE for a better future.

New Look, New Record: KLN Rebrands

Supporting UNICEF HK with 286-Child Coin Toss for The GUINNESS WORLD RECORDS™ Attempt


HONG KONG SAR – Media OutReach Newswire – 27 April 2025 – KLN Logistics Group Limited (“KLN”; Stock Code 0636.HK) today announced the official launch of its rebranding initiative with a grand event held at its Hong Kong Headquarters. 286 children from various schools across Hong Kong collaborated to attempt the GUINNESS WORLD RECORDS TM Title for “Most People Playing Heads or Tails Simultaneously”. The children learned about the history of coins and Hong Kong’s development before using the coins to decorate a special sculpture, demonstrating KLN’s commitment to supporting Hong Kong Committee for UNICEF (“UNICEF HK”), reflecting its international presence and dedication to diversity and inclusion.

From left: GUINNESS WORLD RECORDS™ Official Adjudicator; Vic Cheung, Executive Director and Chief Executive Officer of KLN; Judy Chen, Chairman of UNICEF HK; and Hon Bing-wah, Hong Kong designer and artist.
From left: GUINNESS WORLD RECORDS™ Official Adjudicator; Vic Cheung, Executive Director and Chief Executive Officer of KLN; Judy Chen, Chairman of UNICEF HK; and Hon Bing-wah, Hong Kong designer and artist.

This event is a key component of KLN’s rebranding, embodying the KLN’s long-standing commitment to community care and sustainable development. Vic Cheung, Executive Director and Chief Executive Officer of KLN, said, “KLN firmly believes that corporate development and social responsibility go hand in hand. Through this event, we aim to unite the community, demonstrate our commitment to supporting the community through concrete actions, and improve the living conditions of vulnerable children around the world, creating a brighter future for them.”

The event inspired children by instilling the belief that each of them has the power to make a difference. Not only did they participate in a world record attempt, but their act of placing coins at the base of the “Token of Appreciation” sculpture symbolizes that every young person can contribute to making the world a better place. It underscores that no effort is too small to support the survival, development, protection, and participation rights of children worldwide. This initiative also highlights the shared commitment of KLN and UNICEF HK to advancing global child health, nutrition, sanitation, education, and other related rights. Through their involvement, these children are making a meaningful impact, drop by drop, towards creating positive change in the world.

New Look, New Record: KLN Rebrands Supporting UNICEF HK with 286-Child Coin Toss for The GUINNESS WORLD RECORDS™ Attempt

New Look, New Record: KLN Rebrands Supporting UNICEF HK with 286-Child Coin Toss for The GUINNESS WORLD RECORDS™ Attempt_

Token of Appreciation: A Symbol of Goodwill, Reflecting Hong Kong’s Spirit

To commemorate this occasion, KLN commissioned renowned Hong Kong designer and artist Professor Hon Bing-wah to create a sculpture titled “Token of Appreciation”, with each coin representing a small token of gratitude contributing to a larger expression of thanks. The Chinese name also carries profound meaning, symbolizing the “abundance” goodwill (“yu” in Chinese) generated from the donated coins collected by UNICEF HK – coins that are no longer in circulation or exchangeable – to benefit the community, embodying the spirit of finding joy in helping others. The designer intentionally incorporated the word “yi” (meaning “intention” or “meaning” in Chinese), expressing gratitude and also echoing the Cantonese word for “good fortune” (“yu yi”), symbolizing auspiciousness. This sculpture will be permanently displayed in the lobby of the Kerry Cargo Centre, where KLN’s Headquarters is located.

The fish-shaped sculpture, meticulously crafted with various international coins, draws inspiration from bronze fish-shaped currency from the Yin-Shang Dynasty. It symbolizes abundance and prosperity, recalling Hong Kong’s origins as a fishing village and celebrating its transformation into a global financial hub. The coins, forming the fish’s scales, create a shimmering effect, resembling stars in the long river of history, reflecting Hong Kong’s unity, perseverance, and forward-looking spirit. It commemorates the achievements of past generations and inspires future ones. The overall fluid and harmonious design embodies a continuous flow of energy, signifying Hong Kong’s unwavering core values amidst change and its soaring progress through continuous development.

Ms. Judy Chen, Chairman of UNICEF HK, expressed her gratitude to KLN for the donation made in conjunction with this event to support children in need worldwide. She stated, “This donation will be used to support UNICEF’s work in child health, nutrition, water, sanitation and hygiene, education, and other child rights-related areas globally, creating a better future for children in need.”

This event fully demonstrates KLN’s commitment to strengthening community ties, promoting sustainable development, and encouraging innovative thinking, creating greater value for clients and the community. KLN will continue to serve its clients with excellence and actively give back to society. KLN is also committed to empowering its clients to reach new heights of success through its comprehensive logistics solutions.

Vic Cheung concluded, “Looking ahead, KLN will continue to uphold the belief of ‘leadership through action,’ serve the community with humility, and collaborate with all sectors to build a better Hong Kong.”

Vic Cheung (centre), Executive Director and Chief Executive Officer of KLN; Judy Chen (fifth from the right), Chairman of UNICEF HK; Hon Bing-wah (fifth from the left), Hong Kong designer and artist; together with other officiating guests.
Vic Cheung (centre), Executive Director and Chief Executive Officer of KLN; Judy Chen (fifth from the right), Chairman of UNICEF HK; Hon Bing-wah (fifth from the left), Hong Kong designer and artist; together with other officiating guests.

Hashtag: #KLN

The issuer is solely responsible for the content of this announcement.

About KLN Logistics Group Limited (Stock Code 0636.HK)

KLN is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.

With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world’s emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.

KLN generated a revenue* of close to HK$60 billion in 2024. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.

* For continuing operations only